Sutro Biopharma Inc. (STRO) Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at ASH

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. ROIV
6. AAPL
7. HOOD
8. QCOM
9. ACN
10. AZN

Go back to Sutro Biopharma Inc. (STRO) Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at ASH
(NASDAQ: STRO) Delayed: 19.10 -0.97 (4.83%)
Previous Close $20.07    52 Week High $ 
Open $19.61    52 Week Low $ 
Day High $19.76    P/E N/A 
Day Low $19.04    EPS $ 
Volume 153,540